...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data
【24h】

Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data

机译:差分变异分析能够使用单细胞RNA测序数据检测肿瘤异质性

获取原文
获取原文并翻译 | 示例
           

摘要

Tumor heterogeneity provides a complex challenge to cancer treatment and is a critical component of therapeutic response, disease recurrence, and patient survival. Single-cell RNA-sequencing (scRNA-seq) technologies have revealed the prevalence of intratumor and intertumor heterogeneity. Computational techniques are essential to quantify the differences in variation of these profiles between distinct cell types, tumor subtypes, and patients to fully characterize intratumor and intertumor molecular heterogeneity. In this study, we adapted our algorithm for pathway dysregulation, Expression Variation Analysis (EVA), to perform multivariate statistical analyses of differential variation of expression in gene sets for scRNA-seq. EVA has high sensitivity and specificity to detect pathways with true differential heterogeneity in simulated data. EVA was applied to several public domain scRNA-seq tumor datasets to quantify the landscape of tumor heterogeneity in several key applications in cancer genomics such as immunogenicity, metastasis, and cancer subtypes. Immune pathway heterogeneity of hematopoietic cell populations in breast tumors corresponded to the amount of diversity present in the T-cell repertoire of each individual. Cells from head and neck squamous cell carcinoma (HNSCC) primary tumors had significantly more heterogeneity across pathways than cells from metastases, consistent with a model of clonal outgrowth. Moreover, there were dramatic differences in pathway dysregulation across HNSCC basal primary tumors. Within the basal primary tumors, there was increased immune dysregulation in individuals with a high proportion of fibroblasts present in the tumor microenvironment. These results demonstrate the broad utility of EVA to quantify intertumor and intratumor heterogeneity from scRNA-seq data without reliance on low-dimensional visualization.
机译:肿瘤异质性为癌症治疗提供了复杂的挑战,是治疗反应,疾病复发和患者存活的关键组分。单细胞RNA测序(SCRNA-SEQ)技术揭示了肠内和Intertumor异质性的患病率。计算技术对于量化不同细胞类型,肿瘤亚型和患者之间这些谱的变化的差异是必不可少的,以完全表征肠和Intertumor分子异质性。在该研究中,我们改编了我们对途径失调,表达变异分析(EVA)的算法,以对ScrNA-SEQ基因组中表达的差异变化进行多元统计分析。 EVA具有高灵敏度和特异性,可以检测模拟数据中具有真正差异异质性的途径。 EVA应用于若干公共领域ScrNA-SEQ肿瘤数据集,以量化癌症基因组学的几个关键应用中肿瘤异质性景观,例如免疫原性,转移和癌症亚型。乳腺肿瘤中造血细胞群的免疫途径异质性对应于每个人的T细胞曲目中存在的多样性量。来自头部和颈部鳞状细胞癌(HNSCC)原发性肿瘤的细胞在途径上具有比来自转移的细胞显着更高的异质性,与克隆过度的模型一致。此外,HNSCC基础原发性肿瘤的途径失调差异差异显着差异。在基础原发性肿瘤内,在肿瘤微环境中存在具有高比例的成纤维细胞的个体的免疫失调增加。这些结果证明了EVA从SCRNA-SEQ数据量化Intertumor和腹腔内异质性的广泛效用,而无需依赖低维可视化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号